Tarsus Pharmaceuticals, Inc.
TARS- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001819790
In the last 90 days, Tarsus Pharmaceuticals, Inc. insiders filed 0 open-market purchases and 6 sales; 256 institutions reported holding it in 13F filings for Q2 2026, worth $2.98B in total; no superinvestor holds it.
Q3 2021 vs. Q2 2021
How the institutions holding Tarsus Pharmaceuticals, Inc. changed between Q2 2021 and Q3 2021.
All holders in Q3 2021All holders in Q2 2021
| Measure | Q2 2021 | Q3 2021 | Change |
|---|---|---|---|
| Holders | 44 | 44 | 0 |
| Shares | 13.1M | 12.9M | −192.2K (−1.5%) |
| Value | $378.5M | $277.4M | −$101.2M (−26.7%) |
New holders (6)
Institutions that held Tarsus Pharmaceuticals, Inc. at the end of Q3 2021 but not at the end of Q2 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Sands Capital Ventures, LLC | 260,000 | $5.60M | 0.84% |
| Wells Fargo & Company | 9,784 | $210.0K | 0.00% |
| UBS Group AG | 500 | $11.0K | 0.00% |
| Advisor Group Holdings, Inc. | 200 | $4.00K | 0.00% |
| Parallel Advisors, LLC | 44 | $1.00K | 0.00% |
| American Portfolios Advisors | 39 | $840 | 0.00% |
Sold out (6)
Institutions that held Tarsus Pharmaceuticals, Inc. at the end of Q2 2021 and filed for Q3 2021 without it.
| Institution | Shares, Q2 2021 | Value, Q2 2021 |
|---|---|---|
| Sands Capital Management, LLC | 260,000 | $7.54M |
| Altium Capital Management LP | 70,573 | $2.04M |
| Pura Vida Investments, LLC | 16,686 | $484.0K |
| State of Wisconsin Investment Board | 8,600 | $249.0K |
| Hunter Perkins Capital Management, LLC | 7,780 | $225.0K |
| Signaturefd, LLC | 27 | $1.00K |